Akero Therapeutics Inc (NAS:AKRO)
$ 20.32 0.18 (0.89%) Market Cap: 1.41 Bil Enterprise Value: 525.23 Mil PE Ratio: 0 PB Ratio: 1.66 GF Score: 41/100

Akero Therapeutics Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript

Oct 17, 2022 / 04:00PM GMT
Release Date Price: $39.85 (+3.51%)
Ed Arce
H.C. Wainwright & Co. - Analyst

Hello, and good afternoon. My name is Ed Arce, and I'm with H.C. Wainwright. And I'm pleased to have you join us for the 6th Annual H.C. Wainwright NASH Investor Conference. I'm very pleased to have our next presenting company, Akero Therapeutics, ticker AKRO. And joining me from Akero are: Andrew Cheng, the CEO; Tim Rolph, the Chief Scientific Officer; and joining us in a couple of minutes, Kitty Yale, Chief Development Officer.

So welcome, everyone.

Andrew Cheng
AKERO THERAPEUTICS, INC. - President & CEO

Thank you, Ed, for having us.

Questions & Answers

Ed Arce
H.C. Wainwright & Co. - Analyst

Absolutely, glad you're hear. So let's start with Andrew, if you could, a quick overview of Akero. And in particular, describing your potential best-in class FGF21 fusion protein EFX and its differentiated mechanism.

Andrew Cheng
AKERO THERAPEUTICS, INC. - President & CEO

Sure. I'll begin that question

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot